신속 유전자 검사 키트 시장 분석 및 예측(-2035년) : 유형, 제품 유형, 기술, 구성 요소, 용도, 프로세스, 최종사용자, 기능, 솔루션, 단계

The global Rapid Genetic Testing Kits Market is projected to grow from $495.3 Million in 2025 to $758.9 Million by 2035, at a compound annual growth rate (CAGR) of 4.3%. The Rapid Genetic Testing Kits Market is witnessing increasing demand as healthcare providers prioritize shorter diagnostic turnaround times, decentralized testing, and precision medicine. Adoption is expanding across oncology, infectious diseases, rare diseases, metabolic disorders, and inherited conditions. Manufacturers are focusing on compact instruments, multiplex testing, automated workflows, and simplified sample preparation to improve testing efficiency. Growing integration of molecular diagnostics with bioinformatics and digital health platforms is strengthening clinical utility and enabling faster interpretation of genetic results. Healthcare systems are also increasingly incorporating genetic information into treatment selection and disease-risk assessment, supporting broader utilization of rapid testing technologies across hospitals, specialty clinics, diagnostic laboratories, and near-patient care settings.

Reagents and consumables represent the recurring component base, including amplification reagents, primers, probes, cartridges, extraction materials, and sample-collection products required for rapid molecular workflows. Instruments include compact PCR, isothermal amplification, sequencing, and automated detection platforms designed to reduce hands-on processing and turnaround time. Software supports variant interpretation, automated result generation, data management, and integration with laboratory information systems, while services encompass testing, interpretation, technical support, and workflow implementation. Increasing demand for decentralized diagnostics, automation, multiplex testing, and integrated workflows is encouraging suppliers to develop faster, more user-friendly platforms with improved analytical sensitivity and operational scalability.

Oncology represents a significant application area as rapid genetic testing supports tumor profiling, mutation identification, therapy selection, and companion diagnostic workflows. Infectious disease applications increasingly use molecular genetic detection to identify pathogens and resistance-associated variants rapidly. Cardiovascular and neurological testing enables identification of inherited risk factors and disease-associated mutations, while metabolic testing supports diagnosis of inherited biochemical disorders. Rare-disease applications benefit particularly from shortened diagnostic pathways because rapid genomic analysis can reduce prolonged diagnostic uncertainty. Broader adoption is expected as clinicians increasingly integrate molecular information into precision treatment, early diagnosis, and personalized disease-management decisions.

Geographical Overview

North America maintains a strong position due to advanced molecular diagnostic infrastructure, established genomic laboratories, high healthcare expenditure, and widespread adoption of precision medicine. Demand is supported by oncology testing, rare-disease diagnosis, pharmacogenomics, infectious disease surveillance, and decentralized molecular platforms. A mature biotechnology ecosystem involving diagnostic developers, sequencing companies, hospitals, and research institutions supports product development and commercialization. Strong regulatory frameworks, established reimbursement pathways, extensive clinical research capabilities, and collaborations between healthcare providers and technology companies further strengthen the regional market. Continued investment in genomic medicine, laboratory automation, and rapid diagnostic technologies is expected to sustain adoption across clinical and research applications.

Asia Pacific is developing into an important expansion market as healthcare systems invest in genomic infrastructure, molecular laboratories, sequencing capabilities, and precision-diagnostic technologies. Rising awareness of hereditary disorders, increasing cancer burden, expanding healthcare expenditure, and improving access to advanced diagnostics are supporting adoption. Investments in genomic medicine and laboratory automation are enabling faster testing workflows in major healthcare centers, while domestic biotechnology ecosystems are strengthening manufacturing and distribution capabilities. The region offers substantial demand potential across oncology, infectious diseases, metabolic disorders, and rare diseases. Expanding healthcare infrastructure, declining technology costs, and increasing institutional emphasis on genomic healthcare are expected to support continued market development.

Key Trends and Drivers

Genomics Goes Faster with Next Generation Rapid Testing:

Integration of rapid genetic testing with decentralized and automated diagnostic workflows is reshaping the market, with developers emphasizing compact instruments, multiplex assays, simplified sample preparation, and faster result interpretation. Rapid whole-genome sequencing, targeted gene panels, and cartridge-based molecular systems are increasingly being designed for hospitals, intensive-care environments, specialty clinics, and near-patient testing. Concurrent integration of bioinformatics and cloud-enabled interpretation is improving the ability to convert complex genomic data into actionable clinical information, supporting broader adoption of precision diagnostics.

Precision Medicine Accelerates Demand for Rapid Genetic Insights:

The growing clinical need for faster diagnosis and treatment selection is accelerating demand for rapid genetic testing kits. Genetic information increasingly supports diagnosis of inherited disorders, cancer-risk assessment, tumor profiling, and personalized treatment decisions, while shorter turnaround times can improve clinical decision-making where conventional testing may delay intervention. Increasing adoption of precision medicine, rising awareness of genetic disorders, and advances in PCR, NGS, automation, and bioinformatics are strengthening the value proposition of rapid testing. The FDA recognizes genetic and genomic testing as an important component of precision medicine, particularly for identifying variants that can support diagnosis and treatment decisions.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by Component
• 2.8 Key Market Highlights by Functionality
• 2.9 Key Market Highlights by Solutions
• 2.10 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Diagnostic Kits
  • 4.1.2 Carrier Testing Kits
  • 4.1.3 Prenatal Testing Kits
  • 4.1.4 Newborn Screening Kits
  • 4.1.5 Pharmacogenomic Testing Kits
  • 4.1.6 Predictive and Presymptomatic Testing Kits
  • 4.1.7 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Reagents and Consumables
  • 4.2.2 Instruments
  • 4.2.3 Software
  • 4.2.4 Others
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Polymerase Chain Reaction (PCR)
  • 4.3.2 Next-Generation Sequencing (NGS)
  • 4.3.3 Microarray
  • 4.3.4 Isothermal Amplification
  • 4.3.5 Others
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Oncology
  • 4.4.2 Infectious Diseases
  • 4.4.3 Genetic Disorders
  • 4.4.4 Cardiovascular Diseases
  • 4.4.5 Neurological Disorders
  • 4.4.6 Others
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals and Clinics
  • 4.5.2 Diagnostic Laboratories
  • 4.5.3 Academic and Research Institutes
  • 4.5.4 Pharmaceutical and Biotechnology Companies
  • 4.5.5 Others
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 Sample Collection
  • 4.6.2 DNA Extraction
  • 4.6.3 Amplification
  • 4.6.4 Detection
  • 4.6.5 Analysis
  • 4.6.6 Others
• 4.7 Market Size & Forecast by Component (2020-2035)
  • 4.7.1 Hardware
  • 4.7.2 Software
  • 4.7.3 Services
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Functionality (2020-2035)
  • 4.8.1 Point-of-Care Testing
  • 4.8.2 Laboratory Testing
  • 4.8.3 Others
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Integrated Systems
  • 4.9.2 Standalone Systems
  • 4.9.3 Others
• 4.10 Market Size & Forecast by Stage (2020-2035)
  • 4.10.1 Research and Development
  • 4.10.2 Clinical Testing
  • 4.10.3 Commercialization
  • 4.10.4 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Process
    • 5.2.1.7 Component
    • 5.2.1.8 Functionality
    • 5.2.1.9 Solutions
    • 5.2.1.10 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Process
    • 5.2.2.7 Component
    • 5.2.2.8 Functionality
    • 5.2.2.9 Solutions
    • 5.2.2.10 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Process
    • 5.2.3.7 Component
    • 5.2.3.8 Functionality
    • 5.2.3.9 Solutions
    • 5.2.3.10 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Process
    • 5.3.1.7 Component
    • 5.3.1.8 Functionality
    • 5.3.1.9 Solutions
    • 5.3.1.10 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Process
    • 5.3.2.7 Component
    • 5.3.2.8 Functionality
    • 5.3.2.9 Solutions
    • 5.3.2.10 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Process
    • 5.3.3.7 Component
    • 5.3.3.8 Functionality
    • 5.3.3.9 Solutions
    • 5.3.3.10 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Process
    • 5.4.1.7 Component
    • 5.4.1.8 Functionality
    • 5.4.1.9 Solutions
    • 5.4.1.10 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Process
    • 5.4.2.7 Component
    • 5.4.2.8 Functionality
    • 5.4.2.9 Solutions
    • 5.4.2.10 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Process
    • 5.4.3.7 Component
    • 5.4.3.8 Functionality
    • 5.4.3.9 Solutions
    • 5.4.3.10 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Process
    • 5.4.4.7 Component
    • 5.4.4.8 Functionality
    • 5.4.4.9 Solutions
    • 5.4.4.10 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Process
    • 5.4.5.7 Component
    • 5.4.5.8 Functionality
    • 5.4.5.9 Solutions
    • 5.4.5.10 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Process
    • 5.4.6.7 Component
    • 5.4.6.8 Functionality
    • 5.4.6.9 Solutions
    • 5.4.6.10 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Process
    • 5.4.7.7 Component
    • 5.4.7.8 Functionality
    • 5.4.7.9 Solutions
    • 5.4.7.10 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Process
    • 5.5.1.7 Component
    • 5.5.1.8 Functionality
    • 5.5.1.9 Solutions
    • 5.5.1.10 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Process
    • 5.5.2.7 Component
    • 5.5.2.8 Functionality
    • 5.5.2.9 Solutions
    • 5.5.2.10 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Process
    • 5.5.3.7 Component
    • 5.5.3.8 Functionality
    • 5.5.3.9 Solutions
    • 5.5.3.10 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Process
    • 5.5.4.7 Component
    • 5.5.4.8 Functionality
    • 5.5.4.9 Solutions
    • 5.5.4.10 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Process
    • 5.5.5.7 Component
    • 5.5.5.8 Functionality
    • 5.5.5.9 Solutions
    • 5.5.5.10 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Process
    • 5.5.6.7 Component
    • 5.5.6.8 Functionality
    • 5.5.6.9 Solutions
    • 5.5.6.10 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Process
    • 5.6.1.7 Component
    • 5.6.1.8 Functionality
    • 5.6.1.9 Solutions
    • 5.6.1.10 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Process
    • 5.6.2.7 Component
    • 5.6.2.8 Functionality
    • 5.6.2.9 Solutions
    • 5.6.2.10 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Process
    • 5.6.3.7 Component
    • 5.6.3.8 Functionality
    • 5.6.3.9 Solutions
    • 5.6.3.10 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Process
    • 5.6.4.7 Component
    • 5.6.4.8 Functionality
    • 5.6.4.9 Solutions
    • 5.6.4.10 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Process
    • 5.6.5.7 Component
    • 5.6.5.8 Functionality
    • 5.6.5.9 Solutions
    • 5.6.5.10 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Thermo Fisher Scientific
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Roche Diagnostics
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Abbott Laboratories
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Qiagen
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Illumina
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Bio-Rad Laboratories
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Hologic
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 PerkinElmer
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Becton Dickinson
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Danaher Corporation
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Agilent Technologies
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Siemens Healthineers
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Genomic Health
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Myriad Genetics
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Luminex Corporation
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Cepheid
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Biocartis
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Fulgent Genetics
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Invitae Corporation
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Oxford Nanopore Technologies
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us